Literature DB >> 31562387

Retina transduction by rAAV2 after intravitreal injection: comparison between mouse and rat.

Mariana S Dias1, Victor G Araujo2, Taliane Vasconcelos2, Qiuhong Li3, William W Hauswirth3, Rafael Linden2, Hilda Petrs-Silva4.   

Abstract

Adeno-associated virus vectors (rAAV) are currently the most common vehicle used in clinical trials of retinal gene therapy, usually delivered through subretinal injections to target cells of the outer retina. However, targeting the inner retina requires intravitreal injections, a simple and safe procedure, which is effective for transducing the rodent retina, but still of low efficiency in the eyes of primates. We investigated whether adjuvant pharmacological agents may enhance rAAV transduction of the retinas of mouse and rat after intravitreal delivery. Tyrosine kinase inhibitors were highly efficient in mice, especially imatinib and genistein, and promoted transduction even of the outer retina. In rats, however, we report that they were not effective. Even with direct proteasomal inhibition in rats, the effects upon transduction were only minimal and restricted to the inner retina. Even tyrosine capsid mutant rAAVs in rats had a transduction profile similar to wtAAV. Thus, the differences between mouse and rat, in both eye size and the inner limiting membrane, compromise the efficiency of AAV vectors penetration from the vitreous into the retina, and impact the efficacy of strategies developed to enhance intravitreal retinal rAAV transduction. Further improvement of strategies, then are required.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31562387     DOI: 10.1038/s41434-019-0100-9

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  60 in total

1.  Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV.

Authors:  L Dudus; V Anand; G M Acland; S J Chen; J M Wilson; K J Fisher; A M Maguire; J Bennett
Journal:  Vision Res       Date:  1999-07       Impact factor: 1.886

2.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

3.  Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada.

Authors:  Lin Xing; Stephen J Dorrepaal; Jeffrey Gale
Journal:  Can J Ophthalmol       Date:  2014-06       Impact factor: 1.882

4.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.

Authors:  J G Flannery; S Zolotukhin; M I Vaquero; M M LaVail; N Muzyczka; W W Hauswirth
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

5.  Histology of Burkitt's lymphoma.

Authors:  S McClatchie
Journal:  Br Med J       Date:  1971-03-20

6.  Adeno-associated virus gene transfer to mouse retina.

Authors:  R R Ali; M B Reichel; M De Alwis; N Kanuga; C Kinnon; R J Levinsky; D M Hunt; S S Bhattacharya; A J Thrasher
Journal:  Hum Gene Ther       Date:  1998-01-01       Impact factor: 5.695

Review 7.  Taking Stock of Retinal Gene Therapy: Looking Back and Moving Forward.

Authors:  Jean Bennett
Journal:  Mol Ther       Date:  2017-04-05       Impact factor: 12.910

8.  Variations in eyeball diameters of the healthy adults.

Authors:  Inessa Bekerman; Paul Gottlieb; Michael Vaiman
Journal:  J Ophthalmol       Date:  2014-11-05       Impact factor: 1.909

Review 9.  Retinal Gene Therapy: Surgical Vector Delivery in the Translation to Clinical Trials.

Authors:  G Alex Ochakovski; K Ulrich Bartz-Schmidt; M Dominik Fischer
Journal:  Front Neurosci       Date:  2017-04-03       Impact factor: 4.677

10.  Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach.

Authors:  F M Mowat; K R Gornik; A Dinculescu; S L Boye; W W Hauswirth; S M Petersen-Jones; J T Bartoe
Journal:  Gene Ther       Date:  2013-11-14       Impact factor: 5.250

View more
  9 in total

1.  A 2020 vision of ocular gene therapy.

Authors:  Robert E MacLaren
Journal:  Gene Ther       Date:  2020-06-29       Impact factor: 5.250

2.  Pre-retinal delivery of recombinant adeno-associated virus vector significantly improves retinal transduction efficiency.

Authors:  Hanmeng Zhang; Benjamin S Sajdak; Dana K Merriman; Joseph Carroll; Daniel M Lipinski
Journal:  Mol Ther Methods Clin Dev       Date:  2021-06-12       Impact factor: 5.849

Review 3.  Ocular Barriers and Their Influence on Gene Therapy Products Delivery.

Authors:  Bastien Leclercq; Dan Mejlachowicz; Francine Behar-Cohen
Journal:  Pharmaceutics       Date:  2022-05-06       Impact factor: 6.525

Review 4.  Gene Therapy to the Retina and the Cochlea.

Authors:  Ryan Crane; Shannon M Conley; Muayyad R Al-Ubaidi; Muna I Naash
Journal:  Front Neurosci       Date:  2021-03-17       Impact factor: 4.677

Review 5.  The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery.

Authors:  Maya Ross; Ron Ofri
Journal:  Neural Regen Res       Date:  2021-09       Impact factor: 5.135

6.  Delivery of nVEGFi using AAV8 for the treatment of neovascular age-related macular degeneration.

Authors:  Kaiqin She; Jing Su; Qingnan Wang; Yi Liu; Xiaomei Zhong; Xiu Jin; Qinyu Zhao; Jianlu Xiao; Ruiting Li; Hongxin Deng; Fang Lu; Yang Yang; Yuquan Wei
Journal:  Mol Ther Methods Clin Dev       Date:  2022-01-10       Impact factor: 6.698

Review 7.  Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays.

Authors:  Thilo M Buck; Jan Wijnholds
Journal:  Int J Mol Sci       Date:  2020-06-12       Impact factor: 5.923

8.  Neuroprotective Gene Therapy by Overexpression of the Transcription Factor MAX in Rat Models of Glaucomatous Neurodegeneration.

Authors:  Rafael Lani-Louzada; Camila Marra; Mariana Santana Dias; Victor Guedes de Araújo; Carla Andreia Abreu; Vinícius Toledo Ribas; Daniel Adesse; Silvana Allodi; Vince Chiodo; William Hauswirth; Hilda Petrs-Silva; Rafael Linden
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-02-01       Impact factor: 4.799

Review 9.  Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations.

Authors:  Mays Talib; Camiel J F Boon
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2020 May-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.